Pre-treatment carbohydrate antigen 19-9 does not predict the response to neoadjuvant therapy in patients with localized pancreatic cancer
Open Access
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- CA19-9 in Potentially Resectable Pancreatic Cancer: Perspective to Adjust Surgical and Perioperative TherapyAnnals of Surgical Oncology, 2012
- Current Staging Systems for Pancreatic CancerThe Cancer Journal, 2012
- The prognostic and predictive value of serum CA19.9 in pancreatic cancerAnnals of Oncology, 2012
- Management of Patients with Pancreatic Adenocarcinoma: National Trends in Patient Selection, Operative Management, and Use of Adjuvant TherapyJournal of the American College of Surgeons, 2012
- Survival after Resection of Pancreatic Adenocarcinoma: Results from a Single Institution over Three DecadesAnnals of Surgical Oncology, 2011
- Serum CA 19-9 as a Marker of Resectability and Survival in Patients with Potentially Resectable Pancreatic Cancer Treated with Neoadjuvant ChemoradiationAnnals of Surgical Oncology, 2010
- DPC4 Gene Status of the Primary Carcinoma Correlates With Patterns of Failure in Patients With Pancreatic CancerJournal of Clinical Oncology, 2009
- National Failure to Operate on Early Stage Pancreatic CancerAnnals of Surgery, 2007
- Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundiceEuropean Journal of Surgical Oncology, 2000
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987